A



B

	Alanine Transaminase U/L	**Albumin g/dL**	**Alkaline Phosphatase U/L**	**Aspartate Transaminase U/L**	**Blood Urea Nitrogen mg/dL**	**Creatinine mg/dL**	**Total Bilirubin mg/dL**	**Total Protein g/dL**
Reference Range	*0-403*	*2.9-4.0*	*49-172*	*0-552*	*15.2-34.7*	*0.0-0.3*	*0.0-0.2*	*4.7-6.1*
Control	52.9 ± 28.9	3.44 ± 014	68.3 ± 22.6	83.9 ± 53.7	27.3 ± 4.5	0.15 ± 0.03	0.08 ± 0.05	5.7 ± 0.1
CMC2.24	70.9 ± 55.5	3.54 ± 0.17	81.1 ± 17.0	110.3 ± 55.8	28.2 ± 4.1	0.18 ± 0.04	0.05 ± 0.02	5.6 ± 0.3

Supplemental figure 1: A: Body weight progression during the study for vehicle control and CMC2.24 treated mice during the 3 week treatment period. The differences in body weight between the groups are not statistically significant. **B:** Serum levels of multiple biochemical enzymes and markers of liver and kidney function for control and CMC2.24 350 mg/kg at the end of the 3-week treatment period.



Supplemental figure 2: Curcumin, but not CMC2.24, inhibits NF-κB activation in pancreatic cancer cells. Immunoblots of p-p65 and p65 in MIA PaCa-2 cells treated with CMC2.24 or curcumin at 1.5x IC_{50} for 4 h. Results we quantified as the ration between p-p65/p65; *p<0.05 versus control.